Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M

Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range

May 9, 2017 7:00 AM EDT

LAVAL, Quebec, May 9, 2017 /PRNewswire/ --

First Quarter Financial Results Revenues of $2.109 Billion GAAP Net Income of $628 Million GAAP Cash Flow from Operations of $954 Million Adjusted EBITDA (non-GAAP) of $861 Million Adjusted Net Income (non-GAAP) of $273 Million Reduced Debt by $1.3 Billion in the quarter Raising 2017 Full Year Adjusted EBITDA Guidance Range

May 9, 2017 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX)... More